Featured Post from ChristianaCare

Gene Editing Institute Travels to Salem for ‘Innovation Days’ Workshop

Nov 10, 2022

3 min

Eric Kmiec, Ph.D

Education sessions bring CRISPR gene editing to high school students from diverse backgrounds


Scientist-educators from ChristianaCare’s Gene Editing Institute held a workshop using CRISPR in a BoxTM at Salem Academy during Innovation Days in October at the school, located in Winston-Salem, North Carolina. These sessions followed a previous gene editing education workshop with Salem Academy students in January 2022.


CRISPR in a BoxTM is a revolutionary toolkit that allows students to carry out a hands-on gene editing experiment while learning and analyzing the steps involved in a typical gene editing reaction. Scientists from the Gene Editing Institute also taught a condensed lesson about CRISPR gene editing’s utility in medicine and fielded questions from students about jobs in biotechnology, bioethics and sustainability in the lab.


“It’s a really special opportunity that I know I wouldn’t get anywhere else,” said Mathilda Willenborg, a sophomore boarding student from Germany. “And I do feel like I’m learning a lot about gene editing that I definitely didn’t know before. The team makes it really easy and walks us through all the steps.”



Last winter, Salem Academy became the first school in North Carolina to offer CRISPR in a Box as it pivoted its academic focus to STEAM (Science, Technology, Engineering, Art and Math). That first innovative workshop originated as a result of an idea from a ChristianaCare board member who attended Salem Academy.


Gene Editing Institute Founder and Lead Scientist Eric Kmiec, Ph.D., made a virtual appearance as part of the latest sessions to encourage the students to pursue careers and pathways in biotechnology.


“We’re so appreciative of our partnership with Salem Academy,” said Kmiec. “We want to take every chance we get to encourage more women to pursue careers in STEM. Women around the nation, and around the world, should have access to this groundbreaking technology, which will ultimately drastically change the way we treat and cure diseases. If we don’t have young women in that discussion, we’re missing out on valuable experiences and perspectives.”


Salem Academy is the only all-female boarding and day high school on a college campus in the U.S. with a STEM focus. Women are achieving significant progress in STEM fields, representing 45% of students majoring in STEM, according to the Integrated Postsecondary Education Data System. However, women only represent 27% of STEM workers, with wide disparities in income in post-graduation employment. As of 2019, less than 30% of the world’s researchers were women, according to the UNESCO Institute for Statistics. The Gene Editing Institute commits to a mission of diversity and equity in its approach. This workshop reached 10 women, two of whom are international students.


“Our ongoing partnership with the ChristianaCare Gene Editing Institute will help position our aspiring women scientists for future careers in biotechnology, science and medicine,” said Summer McGee, Ph.D., president of Salem Academy and College. “This is the type of experience that sets Salem Academy apart as a national leader in building the next generation of women leaders in STEAM.”


The Gene Editing Institute itself is a national leader in female researchers. Women make up over 80% of scientists within the Institute and fill 75% of the principal investigator roles. The Institute pushes to address the gender gap and promote inclusivity through local outreach and state-spanning programs, like CRISPR in a Box.


“We’re not here to do lip service,” said Brett Sansbury, Ph.D., principal investigator of the Discovery Branch of the Gene Editing Institute. “Too many companies make a plan or promise without any actionable steps. We’re taking those steps and bringing in opportunities for students who otherwise wouldn’t have had them.”


To learn more about how to bring CRISPR in a Box to your school, visit https://geneeditinginstitute.com/products/education.


About CRISPR in a BoxTM

CRISPR in a BoxTM is the leading educational toolkit to teach gene editing. The exercise features a hands-on gene editing experiment, including a live readout within non-infectious E. coli bacteria. These experiments follow a gene editing reaction from beginning to end while teaching students the techniques scientists use to perform these reactions in real laboratory environments. CRISPR in a Box is distributed by Carolina Biological. To learn more, visit https://geneeditinginstitute.com/products/education.

Connect with:
Eric Kmiec, Ph.D

Eric Kmiec, Ph.D

Executive Director and Chief Scientific Officer, The Gene Editing Institute

Dr. Kmiec, a pioneer in the field, has achieved several ground-breaking firsts in CRISPR gene editing.

Gene EditingBiomedical ResearchMolecular Medicine

You might also like...

Check out some other posts from ChristianaCare

3 min

ChristianaCare Launches Organoid Core to Personalize Cancer Treatment

ChristianaCare’s Cawley Center for Translational Cancer Research has unveiled a first-of-its-kind organoid core in a community cancer center program. The new laboratory facility within the Helen F. Graham Cancer Center & Research Institute grows and tests living, patient-derived tumor models, giving doctors and researchers a faster, more precise way to identify the therapies most likely to work for each patient. This innovation could change how cancer is treated in Delaware and serve as a model for community centers nationwide. There are only a handful of organoid core centers, or “tumor-on-a-chip” programs, in the United States, and ChristianaCare’s is the first within a community cancer center setting. What the Organoid Core Does Tumor organoids are tiny, three-dimensional cultures grown from a patient’s tumor tissue. They preserve the genetic and molecular traits of the original tumor, making them far more accurate than traditional cell lines. “These mini-tumors enable researchers to screen drugs faster, identify new biomarkers and discover which treatments are most likely to work for each patient,” said Thomas Schwaab, M.D., Ph.D., Bank of America Endowed Medical Director of ChristianaCare’s Helen F. Graham Cancer Center and Research Institute. “This core is a bridge between the lab and the clinic. By growing living tumor models from cells of individual patients, we can test real-world drug responses and tailor treatments for them in ways that were not possible before.” How It Advances Patient Care The organoid core strengthens the Cawley Center's research capabilities by enabling drug screening and biomarker discovery. It will bank organoids representing the wide variety of tumors seen in the community, giving scientists a realistic system for testing therapies. ChristianaCare treats more than 70 percent of cancer patients in Delaware, giving researchers unique access to treatment-naïve samples. These are tumor tissues that have not yet been exposed to chemotherapy or other therapies. Studying them provides a more accurate picture of how cancer behaves naturally and how it might respond to new treatments. Bringing a new cancer drug to patients is expensive and risky. Estimates show it can cost $1.3 to $2.8 billion, with up to a third spent on preclinical development, and only about one in 10 compounds ever reach human trials. Traditional mouse models often fail to fully mimic human tumors, making early testing less reliable. By using organoid screening, the Cawley Center can test therapies more accurately, reduce costs and failure rates and move promising treatments into clinical trials faster. Combined with existing tissue collection programs, clinical trial infrastructure and community partnerships, these resources create a direct pathway to bring lab discoveries to patients faster. Turning Point in Translational Research “Our goal is to shorten the distance between discovery and treatment,” said Nicholas J. Petrelli, M.D., director of the Cawley Center. “Too many promising drugs fail because early models do not capture the complexity of real tumors. The organoid core helps solve that problem. We can now test therapies in models that reflect the patients we actually serve.” “This is a turning point for translational research in community health,” said Jennifer Sims Mourtada, Ph.D., associate director at the Cawley Center. “Organoid technology lets us study cancer in a way that feels personal. We are not just looking at data points. We are studying living models of a patient’s tumor, which can reveal how that person’s cancer might behave or respond to treatment. This approach brings science closer to the people it is meant to help.” Looking Ahead In the coming months, the organoid core will focus on building a diverse biobank of tumors common in Delaware. Plans include collaborations with academic institutions, shared access for external researchers, and development of immune-tumor co-culture models. By combining advanced technology, strong community partnerships and direct patient access, ChristianaCare and the Cawley Center are showing how translational cancer research can thrive in a community setting, making breakthroughs not only in the lab but also in patients’ lives.

3 min

ChristianaCare Gene Editing Institute Achieves CRISPR Breakthrough That Reverses Chemotherapy Resistance in Lung Cancer

In a major step forward for cancer care, researchers at ChristianaCare’s Gene Editing Institute have shown that disabling the NRF2 gene with CRISPR technology can reverse chemotherapy resistance in lung cancer. The approach restores drug sensitivity and slows tumor growth. The findings were published Nov. 13, 2025 in the online edition of Molecular Therapy Oncology. This breakthrough stems from more than a decade of research by the Gene Editing Institute into the NRF2 gene, a known driver of treatment resistance. The results were consistent across multiple in vitro studies using human lung cancer cell lines and in vivo animal models. “We’ve seen compelling evidence at every stage of research,” said Kelly Banas, Ph.D., lead author of the study and associate director of research at the Gene Editing Institute. “It’s a strong foundation for taking the next step toward clinical trials.” Potential Beyond Lung Cancer The study focused on lung squamous cell carcinoma, an aggressive and common form of non-small cell lung cancer (NSCLC) that accounts for 20% to 30% of all lung cancer cases, according to the American Cancer Society. It’s estimated that over 190,000 people in the U.S. will be diagnosed in 2025. While the research centered on this cancer type, the implications are broader. Overactive NRF2 contributes to chemotherapy resistance in several solid tumors, including liver, esophageal and head and neck cancers. The results suggest a CRISPR-based strategy targeting NRF2 could help resensitize a wide range of treatment-resistant tumors to standard chemotherapy. “This is a significant step toward overcoming one of the biggest challenges in cancer therapy — drug resistance,” Banas said. “By targeting a key transcription factor that drives resistance, we’ve shown that gene editing can re-sensitize tumors to standard treatment. We’re hopeful that in clinical trials and beyond, this is what will allow chemotherapy to improve outcomes for patients and could enable them to remain healthier during the entirety of their treatment regimen.” Targeting a Master Switch for Resistance The research zeroed in on a tumor-specific mutation, R34G, in the NRF2 gene, which acts as a master regulator of cellular stress responses. When overactive, NRF2 helps cancer cells withstand chemotherapy. Using CRISPR/Cas9, the team engineered lung cancer cells with the R34G mutation and successfully knocked out NRF2. This restored sensitivity to chemotherapy drugs such as carboplatin and paclitaxel. In animal models, tumors directly treated with CRISPR to knockout NRF2 grew more slowly and responded better to treatment. “This work brings transformational change to how we think about treating resistant cancers,” said Eric Kmiec, Ph.D., senior author of the study and executive director of the Gene Editing Institute. “Instead of developing entirely new drugs, we are using gene editing to make existing ones effective again.” Editing Reaches Threshold Levels One of the most promising discoveries was that disrupting NRF2 in just 20% to 40% of tumor cells, was enough to improve the response to chemotherapy and shrink tumors. This insight is particularly relevant for clinical use, where editing every cancer cell may not be feasible. To test therapy in mice, the researchers used lipid nanoparticles (LNPs), a non-viral method with high efficiency and low risk of unintended, off-target effects. Sequencing confirmed that the edits were highly specific to the mutated NRF2 gene, with minimal unintended changes elsewhere in the genome. “The power of this CRISPR therapy lies in its precision. It’s like an arrow that hits only the bullseye,” said Banas. “This level of specificity with minimal unanticipated genomic side effects offers real hope for the cancer patients who could one day receive this treatment.”

3 min

New Outpatient Cardiology Practice at Wilmington Hospital Expands Access to Life-Saving Care for Patients with Peripheral Artery Disease

With the opening of a new cardiology practice at its Wilmington campus, ChristianaCare is bringing life-saving treatment for peripheral artery disease (PAD) closer to home for people who live in and around the city of Wilmington. Peripheral artery disease happens when plaque builds up in the arteries and limits blood flow to the legs. This can cause pain, cramping and difficulty walking. If left untreated, it can lead to serious problems like limb loss, heart attack or stroke. “We’re on a mission to improve the heart and vascular health of our community, and one of the key ways we do that is to identify where people need access to care and ensure that it’s convenient, high-quality and accessible. ChristianaCare’s expansion of cardiology services to the Wilmington campus has made it easier for patients in Wilmington and the surrounding community to receive excellent heart and vascular care,” said Kirk Garratt, M.D., MSc, medical director of the Center for Heart and Vascular Health. “Importantly, it’s part of a multi-disciplinary effort to bring a focus on PAD that includes vascular surgery and interventional radiology. We’re expanding those services in the Wilmington community, too.” In Delaware, an estimated 45,000 to 50,000 people are living with PAD. The condition is more common among older adults and those with diabetes, high blood pressure or a history of smoking, all of which are widespread in the state. Because symptoms can be subtle, many people may not know they have it. That’s why awareness and early diagnosis are so important. Anyone who experiences leg pain, numbness or slow-healing sores should talk with their doctor. A simple test can measure blood flow, and with the right treatment or lifestyle changes, people can ease symptoms and lower their risk of serious complications. The new practice, located in the Gateway Building at Wilmington Hospital, 501 West 14th Street, 4th Floor, offers convenient access to diagnosis and treatment in the heart of the city. The practice is open on Wednesdays from 8 a.m. to 12 p.m., and hours will be adjusted based on patient demand. Meet the Cardiologist: Dr. Vikashsingh Rambhujun Board-certified interventional cardiologist Vikashsingh Rambhujun, MBBS, has cared for ChristianaCare patients for more than a decade and now sees patients at the Wilmington practice. Rambhujun earned his medical degree from SSR Medical College in Mauritius. He completed his residency in internal medicine at the NYU Grossman Long Island School in New York and did his fellowship in cardiovascular medicine and interventional cardiology at ChristianaCare. Rambhujun also spent a year doing interventional cardiology and endovascular medicine and interventions at Yale University Hospital in New Haven, Connecticut. His research has been published widely in medical journals. Rambhujun aims to help patients manage PAD before it becomes advanced. When appropriate, he can perform minimally invasive catheter-based procedures to open blockages in the arteries. “We have new patients with blockages that haven’t progressed to the point that they need a procedure, which is where we want to catch them,” Rambhujun said. “We can manage their cholesterol, blood pressure and other risk factors to prevent disease from progressing.” When Rambhujun began practicing in Wilmington, he made it a priority to speak at local community meetings, raising awareness about the warning signs of heart and vascular disease. His message is simple but urgent: don’t wait; seek treatment early. “We’re trying to help people keep their toes and feet,” he said. “When we treat blockages from peripheral artery disease, the difference can be dramatic,” he said. “Patients who once struggled to walk even a short distance because of pain can leave the hospital able to move freely again. Helping someone reclaim their basic freedoms to walk, stay active and enjoy life is incredibly rewarding.”

View all posts
Powered by